At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 38 enrolled
Drug / intervention
Coenzyme Q10 +1 moredrug
Likely dose
Coenzyme Q10 2 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Coenzyme Q10 (Ubiquinone) Supplementation on Ventricular Function of Children With Idiopathic Dilated Cardiomyopathy.A Randomised Clinical Trial
In Brief
A Phase 4 clinical trial evaluating Coenzyme Q10 and Placebo for Dilated Cardiomyopathy. Completed, enrolled 38 participants across 1 site.
Detailed Summary
This study aims to determine the effect of Coenzyme Q10 supplementation on conventional therapy of children with heart failure due to idiopathic dilated cardiomyopathy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDilated Cardiomyopathy
CountriesIran
Collaborators--
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2006
Primary CompletionMar 2008
First PostedApr 2014
TodayJul 2026
First PostedApr 16, 2014
Enrollment StartSep 1, 2006
Primary CompletionMar 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 12.2 years ago
Interventions
Coenzyme Q10drug
dose of 2 mg/kg/day in 2 or 3 divided doses and increased to the maximum dose of 10 mg/kg/day according to the patient's tolerance
Placebodrug
dose of 2 mg/kg/day in 2 or 3 divided doses and increased to the maximum dose of 10 mg/kg/day according to the patient's tolerance